March 5, 2013. Dr. Jennings testifies to the FDA that the risks of using calcitonin to prevent bone fractures in post-menopausal are greater than the potential benefits.
Read More »On Medical Treatments & Products
NCHR Testimony on Gabapentin
March 4, 2013. Dr. Jennings testifies to the FDA that there is not sufficient evidence to support gabapentin as a safe and effective treatment for hot flashes.
Read More »NCHR Testimony on Paroxetine (Brisdelle)
March 4, 2013. Dr. Mary Carol Jennings testifies to the FDA on the risks of using Paroxetine (Brisdelle) to treat hot flashes.
Read More »Statement of Dr. Diana Zuckerman on FDA Approval of New Silicone-Gel Breast Implant Natrelle 410
February 21, 2013. Yesterday the FDA quietly approved yet another questionable style of breast implants, the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Gel Filled Breast Implant made by Allergan, Inc. Unfortunately, Allergan’s studies did not compare the safety and effectiveness of the Natrelle 410 implant to other previously approved silicone gel-filled breast implants on the market.
Read More »Testimony to FDA Advisory Committee on NeuroFlo
December 10, 2012. Dr. Yttri tesifies to the FDA that the clinical utility of the NeuroFlo device for the SENTIS subject population should be carefully assessed, considering both the lack of benefits and increased risks with an unnecessary procedure.
Read More »